Neal Browning receives a shot in the first-stage safety study clinical trial of a potential vaccine for the COVID-19 coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle.
A USA biotechnology company announced the start ofhumantrialsinAustraliaof a vaccine for the coronavirus with hopes of releasing a proven vaccine this year.
The World Health Organization said that a vaccine for COVID-19 may be available in 18 months. For example, Phase 1 and Phase 2 trials are omitted or Phase 1 human trials are starting before information about animal safety is in.
After a promising outcome from trials in rats, an anti-virus vaccine prototype developed by Thai researchers is now being tested in monkeys, with the results expected by September.
According to reports over the weekend, the vaccine was developed in part with the University of Pennsylvania and would help provide inoculation programs to low and medium income societies. The vaccine utilizes a weakened common cold virus, called adenovirus type 5 (Ad5), to deliver genetic material that ultimately trains the immune system to fend off the SARS-CoV-2 virus.
But unlike other potential vaccines which use unproven mRNA methods to stimulate an immune response, this vaccine sends the virus' spike protein directly into the body to stimulate an immune response. They have introduced the "recombinant vaccine". The team says that early trials of adults in Wuhan produced neutralizing antibodies and a response in the cells that protect the body from pathogens.
"Because that certainly will make the whole Olympics and Paralympics much more viable, if we see global transmission rates coming under control over the next four to six months".
"Proving that the vaccine is effective in ferrets is a key milestone in the development pathway", VIDO-InterVac director Dr. Volker Gerdts said in the release.
Foreign Affairs Minister Winston Peters said the strategy outlines how New Zealand will contribute to global efforts by ramping up its own capability, working with the worldwide community and supporting Pacific neighbours in the deployment of a vaccine, once it becomes available.
Moderna Inc. reported the first COVID vaccine results on humans last week.
All doses of vaccination triggered some level of immune response within two weeks.
"I say two years, with the best will in the world". They include nausea, fatigue, pain, fever and headache.
The announcement was made only in the statement, and the data has not been peer-reviewed or published in a medical journal.
If a vaccine is identified, production should be "globally distributed" to guard against "vaccine nationalism", she said.